Roxadustat alleviates the inflammatory status in patients receiving maintenance hemodialysis with erythropoiesis-stimulating agent resistance by increasing the short-chain fatty acids producing gut bacteria

BACKGROUND: Hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs) have improved the treatment of renal anemia, especially in patients resistant to erythropoiesis-stimulating agents (ESAs). HIF facilitates maintain gut microbiota homeostasis, which plays an important role in inflammation...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Xiu-Nan, Liu, Shu-Xin, Wang, Zhen-Zhen, Zhang, Shuang, You, Lian-Lian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10331997/
https://www.ncbi.nlm.nih.gov/pubmed/37430374
http://dx.doi.org/10.1186/s40001-023-01179-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10331997/
https://www.ncbi.nlm.nih.gov/pubmed/37430374
http://dx.doi.org/10.1186/s40001-023-01179-3

Ejemplares similares